H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

Intrinsic Value

The intrinsic value of one HUTCHMED (China) Ltd stock under the Base Case scenario is 21.49 HKD. Compared to the current market price of 27.3 HKD, HUTCHMED (China) Ltd is Overvalued by 21%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H
Worst Case
Base Case
Best Case

Valuation Backtest
HUTCHMED (China) Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for HUTCHMED (China) Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about HUTCHMED (China) Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about HUTCHMED (China) Ltd

Provide an overview of the primary business activities
of HUTCHMED (China) Ltd.

What unique competitive advantages
does HUTCHMED (China) Ltd hold over its rivals?

What risks and challenges
does HUTCHMED (China) Ltd face in the near future?

Summarize the latest earnings call
of HUTCHMED (China) Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for HUTCHMED (China) Ltd.

Provide P/S
for HUTCHMED (China) Ltd.

Provide P/E
for HUTCHMED (China) Ltd.

Provide P/OCF
for HUTCHMED (China) Ltd.

Provide P/FCFE
for HUTCHMED (China) Ltd.

Provide P/B
for HUTCHMED (China) Ltd.

Provide EV/S
for HUTCHMED (China) Ltd.

Provide EV/GP
for HUTCHMED (China) Ltd.

Provide EV/EBITDA
for HUTCHMED (China) Ltd.

Provide EV/EBIT
for HUTCHMED (China) Ltd.

Provide EV/OCF
for HUTCHMED (China) Ltd.

Provide EV/FCFF
for HUTCHMED (China) Ltd.

Provide EV/IC
for HUTCHMED (China) Ltd.

Show me price targets
for HUTCHMED (China) Ltd made by professional analysts.

What are the Revenue projections
for HUTCHMED (China) Ltd?

How accurate were the past Revenue estimates
for HUTCHMED (China) Ltd?

What are the Net Income projections
for HUTCHMED (China) Ltd?

How accurate were the past Net Income estimates
for HUTCHMED (China) Ltd?

What are the EPS projections
for HUTCHMED (China) Ltd?

How accurate were the past EPS estimates
for HUTCHMED (China) Ltd?

What are the EBIT projections
for HUTCHMED (China) Ltd?

How accurate were the past EBIT estimates
for HUTCHMED (China) Ltd?

Compare the revenue forecasts
for HUTCHMED (China) Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of HUTCHMED (China) Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of HUTCHMED (China) Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of HUTCHMED (China) Ltd compared to its peers.

Compare the P/E ratios
of HUTCHMED (China) Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing HUTCHMED (China) Ltd with its peers.

Analyze the financial leverage
of HUTCHMED (China) Ltd compared to its main competitors.

Show all profitability ratios
for HUTCHMED (China) Ltd.

Provide ROE
for HUTCHMED (China) Ltd.

Provide ROA
for HUTCHMED (China) Ltd.

Provide ROIC
for HUTCHMED (China) Ltd.

Provide ROCE
for HUTCHMED (China) Ltd.

Provide Gross Margin
for HUTCHMED (China) Ltd.

Provide Operating Margin
for HUTCHMED (China) Ltd.

Provide Net Margin
for HUTCHMED (China) Ltd.

Provide FCF Margin
for HUTCHMED (China) Ltd.

Show all solvency ratios
for HUTCHMED (China) Ltd.

Provide D/E Ratio
for HUTCHMED (China) Ltd.

Provide D/A Ratio
for HUTCHMED (China) Ltd.

Provide Interest Coverage Ratio
for HUTCHMED (China) Ltd.

Provide Altman Z-Score Ratio
for HUTCHMED (China) Ltd.

Provide Quick Ratio
for HUTCHMED (China) Ltd.

Provide Current Ratio
for HUTCHMED (China) Ltd.

Provide Cash Ratio
for HUTCHMED (China) Ltd.

What is the historical Revenue growth
over the last 5 years for HUTCHMED (China) Ltd?

What is the historical Net Income growth
over the last 5 years for HUTCHMED (China) Ltd?

What is the current Free Cash Flow
of HUTCHMED (China) Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for HUTCHMED (China) Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
HUTCHMED (China) Ltd

Current Assets 1B
Cash & Short-Term Investments 802.5m
Receivables 192.3m
Other Current Assets 53.5m
Non-Current Assets 212.6m
Long-Term Investments 80.5m
PP&E 94.8m
Other Non-Current Assets 37.3m
Current Liabilities 373.3m
Accounts Payable 43.4m
Accrued Liabilities 228.2m
Short-Term Debt 26.5m
Other Current Liabilities 75.2m
Non-Current Liabilities 147.5m
Long-Term Debt 55.6m
Other Non-Current Liabilities 91.9m
Efficiency

Earnings Waterfall
HUTCHMED (China) Ltd

Revenue
610.8m USD
Cost of Revenue
-356.3m USD
Gross Profit
254.5m USD
Operating Expenses
-375.3m USD
Operating Income
-120.8m USD
Other Expenses
78.8m USD
Net Income
-42m USD

Free Cash Flow Analysis
HUTCHMED (China) Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the first half of 2023, the company reported a 164% surge in revenue to over $530 million, mainly from upfront income from Takeda, while oncology product sales grew by 35%. Net profit rebounded from a $163 million loss to a $168 million gain. They're on track to achieve full-year revenue of $450 million to $550 million and aim for profitability by 2025. The fruquintinib U.S. NDA received priority review with potential approval by late 2023, and in-market sales of their novel products grew 16% to $101 million. With a strong cash balance of $850 million and reduced R&D expenditures, the company has streamlined operations towards sustained growth and anticipates at least 6 new compounds launched in China by 2025.

What is Earnings Call?
Fundamental Scores

Profitability Score
Profitability Due Diligence

HUTCHMED (China) Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

HUTCHMED (China) Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

HUTCHMED (China) Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Short-Term Solvency
80/100
Solvency
Score

HUTCHMED (China) Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
HUTCHMED (China) Ltd

Wall Street analysts forecast HUTCHMED (China) Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HUTCHMED (China) Ltd is 40.65 HKD with a low forecast of 27.42 HKD and a high forecast of 53.9 HKD.

Lowest
Price Target
27.42 HKD
0% Upside
Average
Price Target
40.65 HKD
49% Upside
Highest
Price Target
53.9 HKD
97% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for HUTCHMED (China) Ltd?

Click here to dive deeper.

Dividends

HUTCHMED (China) Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for HUTCHMED (China) Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

News

Other Videos

Profile

HUTCHMED (China) Ltd

Country

Hong Kong

Industry

Pharmaceuticals

Market Cap

23.8B HKD

Dividend Yield

0%

Description

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Contact

48th Floor, Cheung Kong Center, 2 Queen's Road Central
+85221281188.0
www.hutch-med.com

IPO

2006-05-19

Employees

1 759

Officers

CEO, Chief Scientific Officer & Executive Director
Dr. Wei-Guo Su B.Sc., Ph.D.
CFO & Executive Director
Mr. Chig Fung Cheng BEc, CA
Company Secretary & Non-Executive Director
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E
Executive VP & Head of Operations
Ms. Yiling Cui
Head of Investor Relations & Capital Strategies
David Ng
Group General Counsel
Mr. Charles George Rupert Nixon
Show More
Senior Vice President of Corporate Management & Communications
Mr. Kin Hung Lee M.B.A.
Senior Vice President of Global Human Resources
Ms. Selina Zhang
Senior Vice President of Business Development & Strategic Alliances
Dr. Qingmei Wang Ph.D.
Executive VP & Chief Commercial Officer- China
Mr. Hong Chen
Show Less

See Also

Discover More
What is the Intrinsic Value of one HUTCHMED (China) Ltd stock?

The intrinsic value of one HUTCHMED (China) Ltd stock under the Base Case scenario is 21.49 HKD.

Is HUTCHMED (China) Ltd stock undervalued or overvalued?

Compared to the current market price of 27.3 HKD, HUTCHMED (China) Ltd is Overvalued by 21%.

Back to Top